Article
From genes to therapeutic targets for psychiatric disorders - what to expect?
Current opinion in pharmacology - 1 Oct 2011
Muglia Pierandrea
Abstract excerpt
Neuropsychiatric disorders as schizophrenia, autism and mood disorders represent one of the leading causes of disability. The cost of bringing a drug to the market is increasing and becoming more risky. Pharmaceutical investments in neuroscience are decreasing. At the same time we are facing an u...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
